The Bristol Histopathology Inquiry Report was finally released on 8th December, and can be found here:
Patient Advocate, Daphne Havercroft, who issued her own report in November,
Report on the Bristol Histopathology Inquiry Nov. 2010
plans a detailed response to the Inquiry Report when she has read it in more detail. Meanwhile, she has provided this initial response:
“I looked at the report to see what the Panel’s Inquiry has done to make Bristol’s Histopathology Services safer for patients, and I conclude very little. The way in which the Inquiry was conducted could possibly lead to a less safe service for Bristol because its outcome is widely regarded as a whitewash.
The Inquiry report seems to be an unnecessarily bloated 258 page document that dwells much on “playground behaviour” between NBT (North Bristol NHS Trust) and University Hospitals Bristol NHS Trust (UHBristol). It is padded out with pasted in extracts of documents and emails which seem to contribute little if anything to the question of whether the UHBristol Histopathology Service is safe and whether managers and doctors did enough to protect patients and are to be held to account for their failings.
The report contains contradictory statements, of which these are only a few examples:
39 The culture of “a Bristol disease which chips away at itself” and attitudes more suitable to the playground than to the NHS must change if there is to be a safe and effective histopathology service for the city’s patients.
It seems that the Panel telling us that the service is not currently safe because the NHS must change before it is safe.
101 Overall there is no evidence to lead us to believe that the department provides anything other than a safe service, although it still has room and need for considerable improvement.
Or is the Panel telling us that the service is safe, despite needing considerable improvement? (How can something confidently be stated to be safe if it has serious shortcomings?)
Does Jane Mishcon think the service is safe or not? Or is she hedging her bets by telling us that there is no evidence that the service is not safe, but is not able to adduce unequivocal evidence that it is safe?
60 We have absolutely no doubt that Dr Sheffield (former Medical Director, UHBristol),was trying to do his best
65 Indeed, we formed the clear impression that this Inquiry was only established because of the articles in Private Eye and that, had it not been for them, the issues would have continued to be ineffectively addressed.
The Report says
75 Although every single error should be taken extremely seriously, the review by the Royal College shows that there were in fact very few cases of misdiagnosis amongst the 26 which were of the kind which no reasonably competent histopathologist should make.
The Panel has not dealt with the crucial question of whether these errors were of the kind that consultant histopathologists, not merely “reasonably competent” histopathologists, would normally make at a major teaching hospital.
76 It should also be remembered that the UHBT histopathologists report about 20,000 cases between them each year. 26 cases have been identified at NBT over almost a decade of such reporting.
This statement does not tell us how many of the 20,000 cases reported each year are UHBristol patients, whose pathology reporting is managed entirely in a department whose culture the Panel describes as “unwilling to acknowledge, let alone learn from, mistakes, and which is based on overconfidence bordering on arrogance”.
In this sort of culture, it seems highly unlikely that any uncertainties relating to UHBristol patients’ diagnoses have been and are openly acknowledged and discussed. The Royal College of Pathologists report on the 26 cases indicates that is indeed the case. It includes such comments as “the serious error is not to have sought a second opinion” and “over-confidence” in diagnosis.
Eighteen months after the Inquiry was instigated, we still have no idea whether the 26 cases are the tip of the iceberg.
The Panel says:
4.17 We were not satisfied with the way in which the 3,500 cases were selected for audit. In our opinion specimens should have been selected only from those specialties where concerns had been raised, namely respiratory, gynaecology, breast and skin…………There is no doubt that the final selection has to some extent diluted the effectiveness of assessing competency in these four specific specialist areas of concern.
4.18 We therefore did the one thing that we could do without spending even more money on a further review with more selective sampling: we invited Professor Peter Furness, the current President of the Royal College of Pathologists, to evaluate the evidence which was available to us and to give us his professional judgement on it.
Concerns about the methodology of the 3,500 audit were raised publicly at the start of the Inquiry. The Panel could have asserted its independence and advised UHBristol to perform a review of the specific areas of concern a year ago. This should have established very quickly whether or not the specialist histopathology services were safe, without the Inquiry incurring more costs and failing to deliver a clear answer about the safety of UHBristol’s service. The Panel did not assert its independence. The Inquiry has cost £700,000 and we still do not know whether the UHBristol respiratory, gynaecology, breast and skin histopathology services are safe.
The Panel’s Terms of Reference did not include examination of the role of the Strategic Health Authority (NHS South West), the Primary Care Trusts (particularly NHS Bristol), and the Avon, Somerset and Wiltshire Cancer Services (ASWCS) Network in responding to the allegations, despite this being a matter of public interest.
Nevertheless, Panel’s report contains this curious statement relating to August 2008 and NHS Bristol:
3.160 When several weeks later nothing had happened, the matter was discussed amongst the Network team and it was agreed that they would inform the Lead Commissioner, which was NHS Bristol.
Mr Pye (ASWCS Medical Director) therefore went to see Deborah Lee, Director of Commissioning at NHS Bristol, and discovered that this was the first that she knew about any concerns about the histopathology department at UHBT.
The Panel seems to have been extremely careless in reporting the evidence presented to it. I provided it with documentary evidence in November 2009 that proves that Ms Lee has known about the concerns since at least October 2007. I reminded Miss Mishcon of this in writing, in September 2010, yet the Inquiry Report contains this error.
The Panel’s own report indicates that Ms Lee knew about the report since February 2008. Obviously this should read February 2009, but is another example of lack of care in reporting facts.
3.207 On 5 February 2008 Deborah Lee wrote to Dr Sheffield with copies to Ms Evans, Dr Morse and Dr Rich: “Can you confirm the status of the external review of pathology services – it is some time since we saw the Terms of Reference and I’d be grateful for an update of progress/findings.
I am conscious that my criticism of the Panel’s conclusions about the safety of UHBristol’s Histopathology Services could be regarded as alarming to patients and the public. I am alarmed that after an Inquiry lasting eighteen months and costing £700,000, I still do not know whether UHBristol’s histopathology service is safe for my family and me. Nor do I know whether NBT’s services can be relied on as its entire team of breast histopathologists has resigned, the last one leaving in March 2011.
The points I have raised make uncomfortable reading. They are matters of public interest and based on facts and evidence available. I hope other families will read the Panel’s report and my report to enable them to decide for themselves whether they trust Bristol’s Histopathology Services.
An example of a good inquiry report is the Oxford Paediatric Cardiac Inquiry Report, Commissioned by the Strategic Health Authority (NHS South Central) not the Trust under investigation. Only forty eight pages long, with no unnecessary padding.
By contrast, it is unfortunate that we have the Bristol Histopathology Inquiry Report – too long, contradictory, unable to positively state that Histopathology Services are safe, with supporting evidence, and containing at least two factual inaccuracies, both relating to the date that NHS Bristol’s Co-Director of Commissioning (responsible for commissioning safe, high quality health services on behalf of local people), first knew about histopathology concerns.
We seem to have an Inquiry Report whose serious shortcomings can only chip away at its credibility with the public.”